Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
RESEARCH TOOLSreports
FHTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.86 - $10.25
Previous CloseN/A
Volume24.60K
Average Volume (3M)150.25K
Market Cap
$331.45M
Enterprise Value$354.51M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.00
Next Earnings
Mar 06, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding55,612,240
10 Day Avg. Volume210,268
30 Day Avg. Volume150,252
Standard Deviation0.34
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.36
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.69
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$11.80Price Target Upside101.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Foghorn Therapeutics News
PremiumStock Analysis & Ideas
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
PremiumCompany Announcements
Foghorn Therapeutics Advances Drug Development in Oncology
PremiumCompany Announcements
Foghorn Therapeutics Sets 2025 Strategic Objectives
PremiumCompany Announcements
Foghorn Therapeutics Board Member Resignation Announced---
Bulls Say, Bears Say
Bulls Say
Financial And Development CapabilityThe company's cash runway of $267.4M positions it to execute 3–4 INDs, providing meaningful opportunities to advance its pipeline.
Market OpportunityThe strategy to inactivate or degrade SMARCA2 in SMARCA-mutated cancers represents a potentially significant market opportunity, accounting for about 5% of all solid tumors.
Pipeline PotentialPipeline beyond SMARCA2 is a source of upside potential, with promising preclinical data for the CBP and EP300 degraders due to their high selectivity.
Bears Say
Development ChallengesThe clinical benefit rate failed to meet the internal benchmark for FHD-286, leading to its discontinuation.
Market PressureShares are expected to face pressure due to the uncertainty posed by the FHD-286 halt and the lack of significant near-term catalysts.
Product DiscontinuationThe discontinuation of FHD-286, a dual-selective inhibitor targeting both SMARCA2 and SMARCA4, has led to recent stock weakness.
---
Ownership Overview
1.32% Insiders
10.98% Mutual Funds
45.40% Other Institutional Investors
37.07% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.86 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $331.45M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 14 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.12.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,612,240 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 8.495%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
---
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (101.02% Upside)
$11.80 (101.02% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 331.9%
Last 30 Days ▲ 331.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.58%
12-Months-Change
Fundamentals
Return on Equity
322.49%
Trailing 12-Months
Asset Growth
-1.61%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
---
FHTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(101.02% Upside)
Technical Analysis
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-9.71%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -9.71% per trade.
---